US Bancorp
TLX icon

US Bancorp’s Telix Pharmaceuticals TLX Stock Holding History

US Bancorp’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$461 Buy
+42
New +$477 ﹤0.01% 4132

Other funds holding TLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.6B AUM 22.09% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Private Advisor Group
Private Advisor Group Morristown, New Jersey $29.9B AUM 19.22% 1-Year Est. Return
Raiffeisen Bank International
Raiffeisen Bank International Vienna, Austria $8.69B AUM 38.11% 1-Year Est. Return
Aubrey Capital Management
Aubrey Capital Management Edinburgh, United Kingdom $115M AUM 51.42% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Brinker Capital Investments
Brinker Capital Investments Berwyn, Pennsylvania $17.5B AUM 20.48% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $100B AUM 26.06% 1-Year Est. Return

US Bancorp's TLX Position: Q3 2026 in Review

US Bancorp opened a new position in Telix Pharmaceuticals (TLX) in Q3 2026: 42 shares worth $461. The stake represents ﹤0.01% of the portfolio and ranks #4132 among its holdings.

42 funds tracked by Wall St. Rank hold TLX as of Q3 2026.

  • US Bancorp held 42 shares of Telix Pharmaceuticals worth $461 as of Q3 2026.
  • Telix Pharmaceuticals was a new US Bancorp position in Q3 2026.
  • Telix Pharmaceuticals made up ﹤0.01% of US Bancorp's portfolio in Q3 2026, its #4132 holding.
  • 42 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q3 2026.

Based on US Bancorp's 13F filing for Q3 2026, filed 5 Nov 2026.